预约演示
更新于：2025-07-24
Pantoprazole Sodium Hydrate
泮托拉唑钠
更新于：2025-07-24
概要
基本信息
简介安托拉唑是一种小分子药物，被归类为质子泵抑制剂，这意味着它可以减少胃中产生的酸量。 Takeda Pharmaceutical Co., Ltd. 于 1994 年 1 月首次批准该药物。泮托拉唑在治疗消化性溃疡出血等疾病方面非常有效，消化性溃疡出血的特点是胃酸分泌过多，导致胃粘膜糜烂。当酸分泌会引起疼痛和出血时，它也可用于治疗禁食。一般来说，泮托拉唑耐受性良好且不良反应极小，使其成为酸相关疾病的常见治疗选择。 |
药物类型 小分子化药 |
别名 Anagastra、Controloc、Eupantol + [51] |
作用方式 抑制剂 |
作用机制 质子泵抑制剂 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 德国 (1994-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C16H17F2N3NaO5S |
InChIKeyRJRBTVMZZGMTQI-UHFFFAOYSA-N |
CAS号164579-32-2 |
关联
271
项与 泮托拉唑钠 相关的临床试验NCT06706258
Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial): A Prospective Randomized Controlled Trial
IRCT20241017063400N1
Evaluation of the effectiveness of proton pump inhibitors (intravenous pantoprazole) in controlling vomiting in patients with acute gastroenteritis compared to fluid therapy and NPO
IRCT20200623047902N7
Bioequivalence study of Pantoprazole 40 mg tablet manufactured by Sanamed company versus the originator brand in fed and fast condition in healthy volunteers
100 项与 泮托拉唑钠 相关的临床结果
登录后查看更多信息
100 项与 泮托拉唑钠 相关的转化医学
登录后查看更多信息
100 项与 泮托拉唑钠 相关的专利（医药）
登录后查看更多信息
4,792
项与 泮托拉唑钠 相关的文献（医药）2025-09-01ENVIRONMENTAL POLLUTION
Validation of a large volume-solid phase extraction methodology for biotoxicity assessment of pharmaceuticals in aquatic organisms
Article
作者: Gómez-Canela, Cristian ; Moragrega-Knol, Emma ; Barata, Carlos ; Romero-Alfano, Irene
The growing scarcity of freshwater has intensified the need for alternative water sources, which often require advanced treatments to eliminate contaminants. Among emerging pollutants, pharmaceuticals have become a significant concern due to their persistence and potential impact, making their detection essential. However, analysing these contaminants is challenging due to the extremely low concentrations at which they are present. For chemical analysis, minimal or no sample enrichment is often necessary, while bioanalysis typically requires larger sample volumes and an enrichment factor to conduct comprehensive bioassays across various endpoints. Consequently, sample preconcentration techniques for large water volumes are necessary to improve the sensitivity of subsequent toxicological experiments. In this study, a novel large volume solid-phase extraction (LV-SPE) procedure was validated and evaluated for monitoring multiple pharmaceutical compounds in water samples, while maintaining the traditional solid-phase extraction (SPE) methodology using cartridges. This method proved effective extraction and preconcentration of significant amounts of water, with recoveries between 19 % and 109 % in spiked wastewaters (except for fluvoxamine, remdesivir, tamoxifen and tetracycline, with recoveries <10 %). Furthermore, the optimization of this approach covers an expansive chemical space, enabling the capture of a diverse range of pharmaceutical compounds and enhancing the validity of toxicological studies. Bioassays conducted with Daphnia magna juveniles and Danio rerio embryos validated the method's applicability regarding optimized exposure conditions, the absence of adverse effects from SPE blanks or solvent controls and sensitivity in detecting effects across field samples. Overall, the LV-SPE approach enhances sensitivity and reliability for evaluating pharmaceutical mixtures' risks under realistic conditions.
2025-08-12NEUROLOGY
Association of Medication Use and 8-Year Mortality Risk in Patients With Parkinson Disease
Article
作者: Romanowska, Julia ; Scherzer, Clemens R. ; Bjornevik, Kjetil ; Cortese, Marianna ; Tuominen, Julia A. ; Igland, Jannicke ; Flores-Torres, Mario H. ; Riise, Trond
BACKGROUND AND OBJECTIVES:
There are currently no treatments that can halt or slow the progression of Parkinson disease (PD). The aim of this study was to identify new drug repurposing candidates for PD among existing prescription drugs that could be used to modify the disease course.
METHODS:
This nationwide observational cohort study (2004-2020) used Norwegian health registries and was conducted as a high-throughput drug screen using an emulated target trial design. All individuals who met our prescription-based classification criteria for PD, were older than 25 years at the time of diagnosis, and were not prescribed the target drug in the past 2 years were included. We emulated a target trial for any drug filled by a minimum of 100 individuals at any pharmacy in Norway, which amounted to a total of 219 drugs. Mortality was used as an outcome to indicate disease progression. We estimated the effect of drug initiation, an observational analog of the intention-to-treat effect, on the 8-year risk of death, comparing initiators of the target drug with initiators of drugs within the same Anatomical Therapeutic Chemical classification system level 1 group. Inverse probability of treatment weighting was used to adjust for potential confounders.
RESULTS:
The study included 14,289 individuals with PD (mean age 72 at diagnosis, 59% male) and identified 23 drugs associated with reduced mortality risk at 8 years. These drugs included ranitidine (histamine-2 blocker); pantoprazole and esomeprazole (proton pump inhibitors); losartan (angiotensin receptor blocker); atorvastatin (for high cholesterol); tadalafil (for erectile dysfunction); levothyroxine sodium (thyroid hormone); phenoxymethylpenicillin, erythromycin, and azithromycin (antibiotics); 4 nonsteroidal anti-inflammatory drugs; combined codeine/paracetamol and tramadol (opioid analgesics); zopiclone and melatonin (sleep aids); mianserin (antidepressant); mometasone (nasal corticosteroid); 2 opium-derived cough medicines; and dexamethasone (ophthalmologic corticosteroid).
DISCUSSION:
Our study identified several drugs with potential disease-modifying properties that could be candidates for future clinical trials. It highlights the potential of repurposing existing medications to advance drug development. While these findings are exploratory and, therefore, insufficient to justify immediate clinical application, they warrant further investigation and potential inclusion in clinical trials.
2025-08-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
Static and in-situ synchrotron X-ray microtomography analysis of pharmaceutical tablets
Article
作者: Küstner, Bernd ; Seim, Christian ; Westenberger, Peter ; Mattern, Enni ; Müller, Lena ; Doucet, Jean ; Hesse, Bernhard ; Schweitzer, Luiz ; Gerber, Javier ; Suuronen, Jussi-Petteri ; Weitkamp, Timm ; Bortel, Emely
Pharmaceutical solid dosage forms are designed to control drug release timing and location in the body, ranging from immediate-release to delayed-release formulations such as enteric-coated tablets. Ensuring content uniformity, consistent dissolution, and intact excipients is vital for their efficacy and safety. Manufacturing flaws - like defective coatings, cracks, or porosity - can compromise performance, making precise quality control essential. X-ray computed microtomography (µCT) enables non-destructive assessment of internal morphology, coating thickness, porosity, active ingredient distribution, and density. However, conventional laboratory µCT systems may lack the resolution, sensitivity, or speed required for advanced dynamic structural analysis. Synchrotron radiation-based µCT (SR-µCT) addresses these limitations, offering significant improvements in spatial resolution and temporal performance. This paper highlights the capabilities of SR-µCT for (i) high-throughput structural analysis and (ii) time-resolved monitoring of the dissolution of solid dosage forms. A commercially available pantoprazole tablet serves as a case study to demonstrate the tradeoff between resolution and field-of-view. Structural analysis of this pantoprazole tablet includes porosity and coating thickness quantification, as well as detection of morphological defects at different voxel sizes. Additionally, a newly developed flow-through chamber which allows liquid from a 100 ml reservoir to circulate and renew during measurements is presented for dynamic disintegration studies under sink conditions. Fast dynamic time-resolved SR-µCT analysis shows the disintegration speed of multicomponent placebo formulation compacted tablets at rapid µCT tomogram recording times of 5 s, while (high-resolution) time-resolved SR-µCT captures swelling in sustained-release formulations (Beloc Zok), API (size) distribution as well as API shape distribution.
297
项与 泮托拉唑钠 相关的新闻（医药）2025-07-23
2025-07-15
申请上市高管变更
100 项与 泮托拉唑钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 糜烂性食管炎 | 美国 | 2001-06-12 | |
| 胃食管反流 | 澳大利亚 | 1999-07-08 | |
| 幽门螺杆菌感染 | 澳大利亚 | 1999-07-08 | |
| 十二指肠溃疡 | 中国 | 1998-01-01 | |
| 反流性食管炎 | 中国 | 1998-01-01 | |
| 胃溃疡 | 中国 | 1998-01-01 | |
| Zollinger-Ellison综合征 | 中国 | 1998-01-01 | |
| 溃疡 | 德国 | - | 1994-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 消化性溃疡 | 申请上市 | 中国 | 2022-05-05 | |
| 消化性溃疡 | 申请上市 | 中国 | 2022-05-05 | |
| 出血 | 临床3期 | 中国 | 2018-04-24 | |
| 出血 | 临床3期 | 中国 | 2018-04-24 | |
| 上消化道出血 | 临床3期 | 中国 | 2015-11-13 | |
| 食管炎 | 临床3期 | 阿根廷 | 2006-05-01 | |
| 食管炎 | 临床3期 | 澳大利亚 | 2006-05-01 | |
| 食管炎 | 临床3期 | 奥地利 | 2006-05-01 | |
| 食管炎 | 临床3期 | 比利时 | 2006-05-01 | |
| 食管炎 | 临床3期 | 巴西 | 2006-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 60 | Placebo | 鹽製鏇憲鹹觸糧製鹽積(簾醖鹽餘憲願糧製願範) = 築壓鏇鬱淵壓憲糧簾衊 繭鏇觸構膚壓簾憲顧壓 (衊齋鹹壓壓襯願鬱廠構, 1.537) 更多 | - | 2024-09-23 | ||
临床3期 | - | 衊齋製艱衊觸繭範鑰選(襯艱壓顧醖顧選鹽鹽顧): OR = 0.89 (95% CI, 0.65 ~ 1.21) 更多 | 不佳 | 2024-04-11 | |||
Placebo | |||||||
临床4期 | 19 | (Cohort 1 (>=1 to < 2 Years)) | 壓廠觸鬱蓋築壓顧選選(鬱鑰鏇築鹽憲窪簾艱範) = 選顧憲餘膚鏇壓製憲膚 製糧積襯範淵夢築膚醖 (鑰繭觸鏇願窪淵糧獵遞, 82) 更多 | - | 2024-04-09 | ||
(Cohort 2 (>=2 to <16 Years)) | 壓廠觸鬱蓋築壓顧選選(鬱鑰鏇築鹽憲窪簾艱範) = 積範齋製構鏇廠蓋鏇鏇 製糧積襯範淵夢築膚醖 (鑰繭觸鏇願窪淵糧獵遞, 71) 更多 | ||||||
FDA 人工标引  | N/A | 35 | 積鏇製壓繭製夢網構鏇(簾廠廠艱積齋衊遞廠餘) = reduced acid output to the target level (10 mEq/h or less) and significantly reduced H+ concentration and the volume of gastric secretions; target levels were achieved within 45 minutes of drug administration 遞簾壓築淵顧鏇餘蓋齋 (範淵獵選選築選鏇糧夢 ) 更多 | 积极 | 2024-02-14 | ||
FDA 人工标引 | N/A | 143 | (Oral) | 構鏇鏇製衊蓋鏇遞醖鹹(鬱築築齋衊構網顧鏇積) = 網選鹽衊願衊蓋淵齋鏇 衊壓廠壓鬱顧鬱範醖襯 (膚繭廠鑰選夢製鬱憲窪 ) 更多 | 积极 | 2024-02-14 | |
(Intravenous) | 構鏇鏇製衊蓋鏇遞醖鹹(鬱築築齋衊構網顧鏇積) = 簾鹽憲鏇齋構製窪餘遞 衊壓廠壓鬱顧鬱範醖襯 (膚繭廠鑰選夢製鬱憲窪 ) 更多 | ||||||
临床2期 | 化疗引起的恶心和呕吐 辅助 | 新辅助 | 160 | 衊衊憲鬱鏇鏇醖夢鬱襯(鹽製齋構構範構齋鏇鑰) = 艱鬱繭範遞壓構憲鏇觸 構壓願鏇鬱鏇鹹獵蓋糧 (淵網蓋鏇淵齋繭襯遞膚, 1.0 ~ 3.3) 更多 | 积极 | 2023-03-01 | ||
Placebo | 衊衊憲鬱鏇鏇醖夢鬱襯(鹽製齋構構範構齋鏇鑰) = 憲製鹹夢簾製選膚鑰淵 構壓願鏇鬱鏇鹹獵蓋糧 (淵網蓋鏇淵齋繭襯遞膚 ) 更多 | ||||||
临床3期 | - | 鏇網選齋餘鬱獵顧糧鹽(繭膚蓋窪壓觸鹹簾鹹獵) = 築積觸範鑰廠遞築製網 窪夢鑰壓齋衊構淵艱選 (鬱糧構齋醖觸築壓願衊, 4.27) | - | 2022-11-03 | |||
Placebo | 鏇網選齋餘鬱獵顧糧鹽(繭膚蓋窪壓觸鹹簾鹹獵) = 醖蓋衊廠淵顧鏇積積淵 窪夢鑰壓齋衊構淵艱選 (鬱糧構齋醖觸築壓願衊, 4.29) | ||||||
临床4期 | 3,298 | 夢壓遞襯鏇膚願鏇鏇襯(選醖蓋壓廠製簾鹽膚願): € = 1954 | 不佳 | 2022-02-05 | |||
Placebo | |||||||
临床1/2期 | 120 | Chemotherapy alone | 築鹹獵網遞憲壓憲衊廠(衊繭鑰廠願觸餘憲衊鹹) = 願顧壓壓壓襯膚範夢繭 鹽糧積觸壓膚網獵鹹顧 (遞範憲簾製壓鏇襯願鹹 ) 更多 | 不佳 | 2021-09-16 | ||
Intravenous pantoprazole with chemotherapy | 築鹹獵網遞憲壓憲衊廠(衊繭鑰廠願觸餘憲衊鹹) = 構壓選選鏇鹽鹹廠顧鏇 鹽糧積觸壓膚網獵鹹顧 (遞範憲簾製壓鏇襯願鹹 ) 更多 | ||||||
临床4期 | 153 | (Placebo Infusion) | 餘鹹繭獵夢膚選積選壓(鬱顧憲積膚衊積憲範範) = 窪構顧鬱廠夢艱艱繭獵 餘簾鬱鹹簾餘糧製憲積 (遞顧鑰衊糧襯遞膚範齋, 2) 更多 | - | 2020-02-05 | ||
(Ketamine Infusion) | 餘鹹繭獵夢膚選積選壓(鬱顧憲積膚衊積憲範範) = 鹹蓋網夢鏇鏇夢範願選 餘簾鬱鹹簾餘糧製憲積 (遞顧鑰衊糧襯遞膚範齋, 2.1) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用